TVAX Biomedical Names Wayne Carter as President and CEO

TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced the decision of the board to hire Dr. Wayne Carter as president and chief executive officer effective immediately.

TVAX Biomedical is planning phase 2 clinical studies for glioblastoma multiforme, an orphan disease for which there is no effective treatment. The TVAX Biomedical technology has demonstrated efficacy in multiple cancer types including glioblastoma and renal cell carcinoma. The company also recognizes the value of working across the nexus of human and animal health. The TVAX vaccine-enhanced adoptive T cell therapy was licensed to Elias Animal Health to develop the technology as cancer immunotherapy for companion animals and, in particular, dogs with osteosarcoma.

Dr. Carter comes with extensive clinical research expertise in both human and animal medicine. His formal training includes a doctorate of veterinary medicine, clinical residency in veterinary internal medicine and a PhD in immunology. He spent 13 years in the pharmaceutical industry and 10 years leading a division at Pfizer human health focused on improving the accuracy of clinical decisions. After Pfizer he was hired by Colgate to lead nutrition research for Hills Pet Nutrition and in 2012 hired to lead the Kansas City Life Science Institute as president and CEO (now BioNexus KC). Dr. Carter has spent most of his career working across the nexus of human and animal medicine also referred to as One Health.

“I am thrilled to accept this role for TVAX Biomedical. I have had the pleasure of working with TVAX chief scientific officer and founder, Gary Wood, and also the CEO of Elias Animal Health, Tammie Wahaus, and am very impressed with the broad application of the technology and clinical efficacy. The therapy could revolutionize cancer treatments because of the efficacy and minimal side effects in comparison to chemotherapeutics that are currently marketed,” remarked Dr. Carter.”

About TVAX Biomedical
TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Immunotherapy is a unique personalized T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. A key distinction between TVAX and other cancer immunotherapy companies is TVAX’s patented T cell treatment. The power of T cells is their demonstrated ability to kill cancer cells, including cancer stem cells, and cause significant numbers of objective clinical responses in treated patients.

The company’s lead candidates, which are focused on treating brain and kidney cancer, are supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies. TVAX plans to initiate a Phase 2b study in newly diagnosed glioblastoma patients in 2020. As part of its ongoing strategy, the company is seeking to establish corporate alliances to support the development of TVAX Immunotherapy For more information visit: www.tvaxbiomedical.com